Background: Vancomycin remains the mainstay of empirical therapy directed against MRSA. National guidelines recommend empirical dosing based on total body weight with trough-level therapeutic drug monitoring (TDM), which may not be optimal in obese and super obese patients. Furthermore, nomograms for empirical vancomycin dosing by estimated kidney function pre-date standardization of creatinine assays.
Introduction
Vancomycin is the primary therapeutic agent used to treat serious infections due to MRSA worldwide; however, its use is limited by exposure-related acute kidney injury (AKI). Current guidance recommends dosing using total body weight (TBW) irrespective of BMI, which leads to the calculation of large, potentially toxic doses in obese adults. 1 Obesity is defined by a BMI .30 kg/m 2 and is divided into three tiers: class I obesity (30-34.9 kg/m 2 ), class II obesity (35-39.9 kg/m 2 ), and class III or morbid obesity (!40 kg/m 2 ). There has been a 10-to 12-fold rise in the prevalence of US adults with BMI !50 kg/m 2 between 1987 to 2010, prompting use of the terms 'super obese' and 'super morbidly obese' to further categorize class III obesity. 2 Traditional weight-based dosing paradigms do not fit these patients. Although a patchwork of alternative body size descriptors exist to address the error associated with weightbased dosing in this population, there is no consensus on their use. A more straightforward dosing paradigm is feasible for compounds such as vancomycin where CL can be estimated through kidney function and doses can be tailored to specific patients with therapeutic drug monitoring (TDM).
The consensus vancomycin TDM guidelines recommend targeting vancomycin serum trough concentrations within the range of 15-20 mg/L for severe MRSA infections as a pragmatic clinical surrogate for AUC values !400 mgÁh/L. 1 However, this paradigm has recently been challenged by the recognition that trough values are an inadequate surrogate for AUC and place patients at risk of vancomycin over-exposure. 3 We have demonstrated that both peak and trough measurements are needed to improve the prediction of vancomycin AUC in the obese. 4 Emerging clinical data confirm that lower total daily doses (TDDs) can still achieve AUC targets and decrease AKI potential despite trough measurements that would be classified as sub-therapeutic. 5, 6 These data are shifting the paradigm away from trough-only monitoring back to the early standard of peak and trough measurement. However, unlike in the first era of two-sample TDM, clinicians are now armed with validated exposure-response (AUC) targets from which to tailor therapy. 7, 8 V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
We readopted peak and trough measurement of vancomycin 5 years ago to individualize maintenance doses based on AUC in patients with a BMI !30 kg/m 2 ; however, we recognize that empirical dosing guidance is not optimal in this population. Importantly, current vancomycin dosing nomograms rely on equations and methods constructed using non-isotopic dilution massspectrometry (IDMS) standardized serum creatinine (SCR) measurements. Implementation of IDMS standardization of creatinine is now almost complete in the United States through the effort of the National Kidney Disease Education Program. 9 Our objective is to retool vancomycin dosing in obese and super obese patients in order to provide an initial dosing strategy that fits the AUC-based dosing paradigm. The current manuscript details the design of a loading and maintenance vancomycin dosing nomogram to optimize care in obese patients with serious MRSA infections based on demographic variables and IDMS-traceable SCR values.
Patients and methods

Study design and patient population
This is a population pharmacokinetic study of obese inpatients treated with vancomycin following implementation of peak and trough concentration TDM at four hospitals within the Morton Plant Mease Health Care system. Obese (BMI !30 kg/m 2 ) adult patients aged 18-90 years who underwent peak and trough vancomycin TDM were eligible for inclusion. Pregnant women and patients receiving ,48 h of therapy were excluded. Additionally, patients with renal impairment or instability at the time of treatment initiation were ineligible. Renal impairment was defined as an estimated creatinine clearance (CL CR ) ,30 mL/min using the CockcroftGault equation with adjusted body weight (adjBW), whereas creatinine instability was defined as an absolute increase in SCR of at least 0.5 mg/dL or a 50% rise from baseline within the first 48 h. This study received institutional review board approval with waiver of informed consent granted prior to any study procedures. A subset of the patients making up the present cohort has been published previously. 4, 10 Vancomycin dosing and monitoring
In July 2013, a pharmacist-driven vancomycin dosing protocol was introduced for obese (BMI !30 kg/m 2 ) patients using peak and trough vancomycin concentrations. 10 Under this protocol, vancomycin peak ($1 h after the end of infusion) and trough ($30 min prior to next dose) concentrations were obtained at steady-state, and patient-specific pharmacokinetic parameters were calculated via the Sawchuk-Zaske method. 11 Empirical dosing consisted of a loading dose to target a peak vancomycin concentration of 30-40 mg/L, capped at 3000 mg. Volume was estimated as 0.8 L/kg of TBW for all patients in the previously published cohort; BMI stratified values of 0.52 L/kg (BMI 40-49.9 kg/m 2 ) and 0.42 L/kg (BMI !50 kg/m 2 ) were used for super obese patients enrolled following publication of the initial data. 10 The maintenance dosing interval was estimated using the Matzke nomogram equation to estimate the elimination rate constant. 12 
Data collection and management
Eligible patients were identified using TheraDoc V R clinical surveillance software (TheraDoc, Inc., Salt Lake City, UT, USA). Data were abstracted from the electronic medical record, and included demographics (age, sex, race), encounter information (admittance and discharge dates, ICU admission), anthropometrics [height, weight, BMI, body surface area (BSA)], laboratory information [SCR, blood urea nitrogen (BUN), albumin], and vancomycin dosing and administration times. Vancomycin concentrations were measured using an immunoturbidimetric assay and SCR was measured using an IDMS-traceable alkaline picrate-kinetic rate blanked assay (Dimension Vista V R System, Siemens Healthcare Diagnostics Inc., Newark, DE, USA). The inter-day coefficient of variation was ,5% for both assays. Various scalars of body size including ideal body weight (IBW), adjBW and lean body weight (LBW) were calculated as previously described. 13 Renal function was estimated as CL CR using the Cockcroft-Gault equation calculated with each scalar of body weight. Demographic data were compared using analysis of variance (ANOVA) for multi-group comparisons of continuous data and the v 2 or Fisher's exact tests for categorical data. All analyses was performed on de-identified data in the R environment. 14 
Pharmacokinetic analysis
Population pharmacokinetic analysis was performed using the nonparametric adaptive grid algorithm within the Pmetrics TM package for the R environment. 14, 15 The base model was parameterized using a onecompartment system with zero-order (constant-rate) infusion and firstorder elimination. Although a two-compartment model has previously been demonstrated to best describe the pharmacokinetics of vancomycin, calculations used clinically in TDM are based on the assumption of a onecompartment system and we have previously demonstrated acceptable precision with such a model in obese patients. 3, 4 The relationships between patient-specific covariates and pharmacokinetic parameters determined by the base model were assessed using linear regression. Covariate-structured models were obtained by iterative addition of covariates to describe CL and volume of the central compartment (V c ), respectively. Discrimination between models was made based on the #2 loglikelihood ratio (#2LL) and Akaike's Information Criterion (AIC) objective functions.
Monte Carlo simulation
Dosing regimens were assessed using 1000-subject Monte Carlo simulations within Pmetrics TM . The final model covariate matrix and model structure was used as the population distribution for the simulation runs. First, vancomycin TDDs from 500 to 5000 mg were assessed without loading doses with 1000 simulated subjects per patient in the original dataset (i.e. 346000 total runs per dose level). Daily doses ,2000 mg were administered once daily, whereas daily doses of !2000 mg were divided and administered every 12 h. Dosing regimens were simulated out to 72 h and the AUC was calculated in 24 h increments (AUC 0-24 , AUC 24-48 , AUC 48-72 ). Next, loading doses were added to the simulated regimens with the goal of obtaining PTA values for efficacy in the first 24 h which approximated values from 48 to 72 h. PTA was defined as a 24 h AUC of !400 mgÁh/L for efficacy and a 24 h AUC of ,700 mgÁh/L for toxicity. 8 Finally, PTA values during each 24 h interval were stratified by both dose and CL in order to determine the dosing regimens that maximized the 24 and 48 h exposures associated with efficacy while minimizing the probability of 72 h exposures associated with toxicity. CL was binned by rounding to the nearest whole number in order to obtain probabilities.
Results
The study sample included 346 obese and super obese adults with BMI values of 30.1-85.7 kg/m 2 . Patients on average were middle aged (range 19-88 years) and well balanced by sex. Despite including only obese patients, there was a wide distribution in TBW (range 69.6-293.6 kg) and height (range 132.1-198.1 cm). Baseline SCR was ,1.0 mg/dL on average (range 0.3-2.5 mg/dL). Additional baseline and demographic data are presented in Table 1 .
The distribution of vancomycin concentrations relative to the preceding dose are displayed in Figure S1 (available as Supplementary data at JAC Online). Robust peak and trough Crass et al. concentration data were available within 24 h of prior dose administration thereby facilitating accurate estimation of both V c and CL. The observed vancomycin concentration-time profile was adequately described using a one-compartment system with population and individual post-Bayesian observed-versus-predicted coefficient of determination (R 2 ) values of 0.31 and 0.99, respectively. In the final population model, CL was best described using a linear combination of a constant and the individual covariates in the Cockcroft-Gault equation (age, SCR, sex, weight) with weight scaled allometrically (CL " h con # h age % AGE # h scr % SCR ! h sex % SEX ! h wt % TBW 0.75 ). Median parameter estimates (h values) for this equation can be found in the footnote to Table 2 . This linear combination of the individual variables was superior to models using estimated CL CR , irrespective of the height and/or weight scalar used (Table S1 ). Model fit was not improved when V c was scaled linearly or allometrically with any measure or scalar of height and/ or weight. The final model population observed-versus-predicted R 2 of 0.45 is an improvement over the base model value without significant change in the individual post-Bayesian value of 0.95 ( Figure S2) . Tables of population pharmacokinetic parameter estimates (h values) and covariance matrices for the onecompartment base model and the final covariate-structured model are available in Tables S2-S5 in order to facilitate validation of these data in diverse clinical settings and direct application to TDM systems employing Bayesian methods.
The mean (coefficient of variation) individual V c and CL estimates from the final population pharmacokinetic model were 74.1 (33.4) L and 5.9 (42.3) L/h, respectively. Using the final population model, 1000-subject Monte Carlo simulations were performed for a wide range of vancomycin TDDs with and without loading. The probabilities of achieving AUC thresholds associated with efficacy and toxicity at 72 h are depicted in Figure 1 for regimens including loading doses. Vancomycin loading doses were necessary to reach 90% probability of attaining AUC 0-24 values of at least 400 mgÁh/L for patients with low vancomycin clearance (CL V ). Importantly, the use of loading doses did not significantly alter the probability of reaching toxic (!700 mgÁh/L) AUC 24-48 or AUC 48-72 values. Table 2 provides a nomogram for empirical dosing based on estimated CL V as well as the associated probabilities of efficacy and toxicity target attainment based on the Monte Carlo simulations. The 5th and 95th percentiles of CL V were 2.3 and 9.9 L/h, respectively; therefore, TDDs .4500 mg were not required to achieve target AUC at clinically relevant values of CL V . Finally, the probability of achieving exposures .700 mgÁh/L in patients with CL V .2 L/h was 0%, suggesting a low potential for toxicity with recommended dosing, but also indicating that few patients would achieve an AUC/MIC .400 at MIC values .1 mg/L.
Discussion
The 2009 consensus vancomycin dosing guidelines recommend loading doses of 25-30 mg/kg followed by maintenance doses of 15-20 mg/kg every 8-12 h with normal renal function. 1 The guidelines suggest calculating doses using TBW in both normal-weight and obese patients; however, clinically this is rarely the case, with multiple strategies published attempting to adjust doses due to concern about over-exposure and toxicity in this patient population. 16 The practice of empirical vancomycin dosing in obese patients is even more heterogeneous amongst individual providers. Diverse dosing strategies, based primarily on anecdotal experience (i.e. clinical judgement), are employed by individual practitioners to mitigate the risk of toxicity in obese patients.
TDM gives the clinician the ability to adjust empirical doses based on patient-specific data. Although the most recent version of the vancomycin dosing guidelines recommends trough-only monitoring, the pendulum appears to be shifting back to peak and (14) 59 (15) 58 (14) 55 (12) Vancomycin dosing in the super obese JAC trough monitoring due to the added precision this offers in estimating the pharmacokinetic parameters necessary for dose adjustment. 5, 6 Two-sample TDM became the standard of care for obese patients treated with vancomycin at our institution in 2013.
We have demonstrated that this monitoring strategy improves the precision of vancomycin dosage adjustments in obese patients; however, room for improvement in the selection of empirical doses remains. 4, 10 Crass et al.
Rybak and Boike 17 demonstrated in 1986 that measured peak and trough concentrations improved precision and reduced bias in vancomycin dosage adjustments over dose-individualization using the Moellering and Matzke nomograms. Although TDM obviates the need for dosage adjustments based only on patient-specific demographic and clinical covariates, empirical dosing still requires some of these assumptions prior to the availability of patientspecific concentration data. Thus, the nomogram remains relevant in the form of regression equations relating CL CR to CL V and body weight to volume, which are still used routinely to determine empirical doses.
The equations most commonly used today in clinical practice were derived from two nomograms published by Matzke et ; however, the use of measured, rather than estimated, CL CR limits extrapolation to the clinical setting where such testing is not routine. Most importantly, these methods pre-date the use of IDMS-traceable creatinine measurements, which can bias these estimates in current practice settings.
Using population pharmacokinetic modelling, we found that a linear combination of the age, SCR, sex and TBW scaled allometrically to an exponent of 0.75 improved the prediction of CL V over the combination of these variables into the single measure of estimated CL CR . The final population pharmacokinetic model described here accounted for 45.0% of the inter-patient variability in observed vancomycin concentrations.
The shift from trough-only to AUC-based monitoring via peak and trough level measurement has important implications, not only for dose adjustments, but for empirical dosing as well. Because 24 h AUC at steady-state is approximated by TDD divided by CL V (AUC 24 " TDD/CL V ), model-predicted CL can be used directly to solve for a patient-specific empirical dose (TDD " AUC target % CL V ). With trough-directed therapy, more complicated calculations involving volume and the elimination rate constant are necessary to predict steady-state trough concentrations, thereby compounding bias with the estimation error of each predicted pharmacokinetic parameter. The CL V estimates in the nomogram presented in Table 2 can be easily calculated manually using readily available patient covariates or implemented directly into electronic medical record dashboards to support empirical dosing in obese patients with adjustments made using twosample monitoring to target AUC.
Several limitations to these data need to be acknowledged. First, information regarding vancomycin indication and patient clinical status was not obtained. Prospective clinical validation in other obese patient populations is necessary prior to widespread implementation, especially in subpopulations with high variability such as the critically ill. Second, because of the distribution of CL V within our sample, dose recommendations could not be provided for patients with very low CL V (,0.5 L/h). Clinical judgement should be used in these patients with the potential for more frequent TDM, ideally consisting of peak and trough concentration monitoring following a loading dose, in order to obtain patient-specific information early in therapy.
The dosing of vancomycin in clinical practice is poised for a renaissance with a shift to TDM targeting AUC rather than trough concentrations. Such a practice will lead to lower TDDs in a clinically meaningful subset of patients. Obese patients, who are intrinsically at higher risk of over-exposure with weight-based empirical dosing, may doubly benefit by empirical dosing strategies to target AUC and dosage adjustment using two-level TDM. Implementation of this model has the potential to improve empirical dosing in obese and super obese patients.
